New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareBronchogen vs Livagen

Bronchogen vs Livagen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Bronchogen
Anti-Aging & Longevity
Livagen
Summary
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
10 mg per day
10 mg per day
Frequency
Daily for 10–30 days
Daily for 10–30 days
Key Benefits
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With